madman
Super Moderator
Pharmacotherapy in Cachexia: A Review of Endocrine Abnormalities and Steroid Pharmacotherapy (2022)
Magdalena Celichowska, Miłosz Miedziaszczyk & Katarzyna Lacka
ABSTRACT
Cachexia is a state of increased metabolism associated with high morbidity and mortality. Dysregulation of cytokines and hormone activity causes reduced protein synthesis and excessive protein breakdown. Various treatments are available, depending on the primary disease and the patient’s state. Besides pharmacological treatment, crucial is nutritional support as well as increasing physical activity. The main purpose of pharmacological treatment is to diminish inflammation, improve appetite and decrease muscle wasting. Therefore a lot of medications aim at proinflammatory cytokines such as Interferon-α or Tumor Necrosis Factor-β, but because of the complicated mechanism of cachexia, the range of targets is very wide. in cachexia treatment, the use of corticosteroids is common, which improve appetite, diminish inflammation, inhibit prostaglandin metabolism, Interleukin-1 activity. They can also decrease protein synthesis and increase protein degradation, which can be prevented by resveratrol. Estrogen analogs, progesterone analogs, testosterone analogs, Selective Androgen Receptor Modulators (SARM), Angiotensin-Converting-Enzyme Inhibitors (ACEI), Nonsteroidal anti-inflammatory drugs (NSAIDs), thalidomide, melatonin, Growth Hormone Releasing Peptide-2 (GHRP-2) may play important role in wasting syndrome treatment as well. However, for the usage of some of them, evidence-based recommendations are not available. This review highlights current therapeutic options for cachexia with a specific focus on steroid therapy.
Introduction
Cachexia, also known as wasting syndrome is a state of increased metabolism, which cannot be compensated by daily caloric intake in the setting of ongoing disease. It manifests with increased muscle mass loss (with or without loss of body fat) and usually fatigue, lack of appetite, apathy, weakness, sleep disturbances, depression, anemia, and early satiety. Furthermore noticed should be problems with food intake from xerostomia stomatitis or inflammatory condition in the oral cavity, pain, nausea, emesis, diarrhea, and depression. Cachexia is very often underestimated as a potential cause of death and also is hard to treat. Proper management of patients with cachexia is crucial to achieving therapeutic success. With the increasing age of society as well as the increasing number of patients with cancer, the incidence of cachexia may also increase (1–4).
*The aim of this review is to summarize current data on the pathophysiology and treatment of cachexia, especially about the endocrinological aspect of that state and steroid therapy. This review will also highlight pharmacologic therapeutic strategies which could be helpful in managing wasting syndromes and also those which need further study. Although nutritional interventions are also important in the management of cachexia, these strategies are outside of the scope of this review.
Pathophysiology of cachexia
There are various conditions, which lead to cachexia, but the most common ones are cancer, AIDS, chronic heart failure (CHF), rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), chronic kidney disease, liver cirrhosis, cystic fibrosis, Crohn’s disease, stroke, degenerative neurological disorders, sepsis, states after spinal cord injuries, malaria or tuberculosis (5).
Pharmacological treatment
Treatment
*Non-steroid pharmacological treatment
*Steroid therapy
Adrenocortical corticosteroids
Progesterone analogs
Testosterone analogs
Estrogens analogs
Non-pharmacological therapy
Conclusion
The range of drugs used in the treatment of cachexia has grown significantly in recent years. The knowledge of the treatment of cachexia is essential for the therapy of patients, which should be selected individually. Dexamethasone and megestrol acetate are the most commonly used steroids for wasting syndromes, and current guidelines support their use in patients with cancer cachexia. Other steroid and non-steroid medications may be used in appropriate patients; however, further studies are needed to recommend their use in cancer cachexia (Table 4).
Magdalena Celichowska, Miłosz Miedziaszczyk & Katarzyna Lacka
ABSTRACT
Cachexia is a state of increased metabolism associated with high morbidity and mortality. Dysregulation of cytokines and hormone activity causes reduced protein synthesis and excessive protein breakdown. Various treatments are available, depending on the primary disease and the patient’s state. Besides pharmacological treatment, crucial is nutritional support as well as increasing physical activity. The main purpose of pharmacological treatment is to diminish inflammation, improve appetite and decrease muscle wasting. Therefore a lot of medications aim at proinflammatory cytokines such as Interferon-α or Tumor Necrosis Factor-β, but because of the complicated mechanism of cachexia, the range of targets is very wide. in cachexia treatment, the use of corticosteroids is common, which improve appetite, diminish inflammation, inhibit prostaglandin metabolism, Interleukin-1 activity. They can also decrease protein synthesis and increase protein degradation, which can be prevented by resveratrol. Estrogen analogs, progesterone analogs, testosterone analogs, Selective Androgen Receptor Modulators (SARM), Angiotensin-Converting-Enzyme Inhibitors (ACEI), Nonsteroidal anti-inflammatory drugs (NSAIDs), thalidomide, melatonin, Growth Hormone Releasing Peptide-2 (GHRP-2) may play important role in wasting syndrome treatment as well. However, for the usage of some of them, evidence-based recommendations are not available. This review highlights current therapeutic options for cachexia with a specific focus on steroid therapy.
Introduction
Cachexia, also known as wasting syndrome is a state of increased metabolism, which cannot be compensated by daily caloric intake in the setting of ongoing disease. It manifests with increased muscle mass loss (with or without loss of body fat) and usually fatigue, lack of appetite, apathy, weakness, sleep disturbances, depression, anemia, and early satiety. Furthermore noticed should be problems with food intake from xerostomia stomatitis or inflammatory condition in the oral cavity, pain, nausea, emesis, diarrhea, and depression. Cachexia is very often underestimated as a potential cause of death and also is hard to treat. Proper management of patients with cachexia is crucial to achieving therapeutic success. With the increasing age of society as well as the increasing number of patients with cancer, the incidence of cachexia may also increase (1–4).
*The aim of this review is to summarize current data on the pathophysiology and treatment of cachexia, especially about the endocrinological aspect of that state and steroid therapy. This review will also highlight pharmacologic therapeutic strategies which could be helpful in managing wasting syndromes and also those which need further study. Although nutritional interventions are also important in the management of cachexia, these strategies are outside of the scope of this review.
Pathophysiology of cachexia
There are various conditions, which lead to cachexia, but the most common ones are cancer, AIDS, chronic heart failure (CHF), rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), chronic kidney disease, liver cirrhosis, cystic fibrosis, Crohn’s disease, stroke, degenerative neurological disorders, sepsis, states after spinal cord injuries, malaria or tuberculosis (5).
Pharmacological treatment
Treatment
*Non-steroid pharmacological treatment
*Steroid therapy
Adrenocortical corticosteroids
Progesterone analogs
Testosterone analogs
Estrogens analogs
Non-pharmacological therapy
Conclusion
The range of drugs used in the treatment of cachexia has grown significantly in recent years. The knowledge of the treatment of cachexia is essential for the therapy of patients, which should be selected individually. Dexamethasone and megestrol acetate are the most commonly used steroids for wasting syndromes, and current guidelines support their use in patients with cancer cachexia. Other steroid and non-steroid medications may be used in appropriate patients; however, further studies are needed to recommend their use in cancer cachexia (Table 4).